# US 2026/0007597 A1 · Compositions and methods for treatment of virus-induced airway fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007597 A1
- Document ID: US20260007597A1
- Status: Published application
- Kind: A1
- Application number: 18/993,347
- Filed: 2023-07-10
- Published: 2026-01-08
- Earliest claimed: 2022-07-12
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Inventors: Peter D. Sun; Rachel Erickson
- Web page: https://patentgrep.com/patent/US20260007597A1

## CPC

- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/381: having five-membered rings
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 38/58: from leeches, e.g. hirudin, eglin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/14: for RNA viruses
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods of treating or inhibiting viral infection-induced airway fibrosis in a subject, the method including administering to the subject an effective amount of a composition including one or more direct thrombin inhibitors or one or more serine protease inhibitors or metalloprotease inhibitors are provided. In some examples, the composition is administered to the subject by inhalation. In particular examples, the viral infection-induced airway fibrosis is a coronavirus infection-induced airway fibrosis.

## Claims

### Claim 1

A method of treating or inhibiting viral infection-induced airway fibrosis in a subject, comprising administering to the subject an effective amount of a composition comprising one or more direct thrombin inhibitors.

### Claim at position 2 (depends on 1)

2, The method of claim 1, wherein the viral infection-induced airway fibrosis is a coronavirus infection-induced airway fibrosis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the coronavirus is severe acute respiratory syndrome (SARS)-CoV-2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administering is by inhalation.

### Claim 5 (depends on 4)

The method of claim 4, wherein the composition is administered as an aerosol.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition is administered using a nebulizer, a dry powder inhaler, or a metered dose inhaler.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

The method of claim 1, wherein the direct thrombin inhibitor is selected from the group consisting of argatroban, dabigatran, ximelagatran, hirudin, lepirudin, desirudin, and bivalirudin.

### Claim 9 (depends on 8)

The method of claim 8, wherein the direct thrombin inhibitor is argatroban or dabigatran.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dose of the argatroban or dabigatran is about 0.1 μg/kg to about 10 mg/kg.

### Claim 11

A method of treating or inhibiting viral infection-induced airway fibrosis in a subject, comprising administering to the subject an effective amount of a composition comprising one or more serine protease inhibitors or metalloprotease inhibitors.

### Claim 12 (depends on 11)

The method of claim 11, wherein the viral infection-induced airway fibrosis is a coronavirus infection-induced airway fibrosis.

### Claim 13 (depends on 12)

The method of claim 12, wherein the coronavirus is severe acute respiratory syndrome (SARS)-CoV-2.

### Claim 14 (depends on 11)

The method of claim 11, wherein the administering is by inhalation.

### Claim 15 (depends on 14)

The method of claim 14, wherein the composition is administered as an aerosol.

### Claim 16 (depends on 15)

The method of claim 15, wherein the composition is administered using a nebulizer, a dry powder inhaler, or a metered dose inhaler.

### Claim 17 (depends on 11)

The method of claim 11, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 18 (depends on 11)

The method of claim 11, wherein the serine protease inhibitor is camostat or nafamostat or the metalloprotease inhibitor is batimastat (BB-94) or prinomastat.

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering to the subject an additional treatment for the viral infection.

### Claim 20 (depends on 19)

The method of claim 19, wherein the additional treatment comprises one or more of an antiviral compound, a corticosteroid, and a monoclonal antibody.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject has a SARS-COV-2 infection and the antiviral compound is one or more of nirmatrelvir, ritonavir, remdesivir, and molnupiravir.

### Claim 22 (depends on 20)

The method of claim 20, wherein the subject has a SARS-COV-2 infection and the monoclonal antibody is bebtelovimab.
